Nordic Pharma to Showcase LACRIFILL Canalicular Gel at AAO 2025 in Orlando

Nordic Pharma to Showcase LACRIFILL Canalicular Gel at AAO 2025

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., is set to unveil its innovative LACRIFILL Canalicular Gel at the American Academy of Ophthalmology (AAO) Annual Meeting, taking place from October 18 to 20, 2025, in Orlando, Florida. This unique therapy targets the symptoms of dry eye, a condition that affects millions globally. The company will also share new patient data and insights from recent studies, emphasizing the positive responses among patients who have used LACRIFILL.

“Eye care professionals are eager to learn about advancements in ophthalmology that can enhance patient care. Therefore, it’s thrilling to reveal that 98.11% of both new and returning users indicated they would seek LACRIFILL again in the future,” stated Dr. Jai Parekh, who serves as the Chief Commercial Officer for Eye Care in the U.S. This enthusiasm reflects the company's commitment to utilizing data to demonstrate the significant impact of LACRIFILL on patient experience.

In conjunction with the AAO meeting, renowned figures in the eye care field, such as Dr. Vance Thompson, Dr. Kayla Karpuk, and Dr. Mark Packer, have been invited to contribute to a forthcoming critical perspectives article focusing on lacrimal occlusion. This paper will be featured in an upcoming edition of the Expert Review of Ophthalmology. Dr. Thompson pointed out the influential role dry eye disease plays in surgical preparations, outcomes, and patient satisfaction regarding cataract and refractive surgeries. He highlighted the versatility of LACRIFILL, which is approved for use for up to six months, underscoring its effectiveness both before and after surgical procedures to optimize ocular surfaces.

The Women in Ophthalmology (WIO) Awards Ceremony and Networking Reception is an anticipated event running concurrently on Saturday, October 18th, at 5:30 p.m. Nordic Pharma proudly serves as the Premier Sponsor of this gathering, further signifying its dedication to supporting women in the ophthalmic field. Dr. Lisa M. Nijm, CEO of WIO, expressed gratitude for Nordic Pharma's ongoing support, celebrating its role in recognizing outstanding contributions by women in ophthalmology and fostering better professional environments for female ophthalmologists.

Attendees are encouraged to visit Nordic Pharma's booth (#1401) for interactive demonstrations of LACRIFILL, where they can also place orders for the product.

The TFOS Dry Eye Workshop (DEWS) III report recently published in the American Journal of Ophthalmology incorporates two crucial studies about Nordic Pharma’s hyaluronic acid canalicular filler. The findings indicate significant improvements in corneal staining and Schirmer test scores three months post-administration. Additionally, a comparative study evaluated LACRIFILL against a commonly utilized hydrogel canalicular plug, concluding that the cross-linked HA filler is both safe and well-tolerated, with substantial enhancements in dry eye symptoms maintained through the six-month mark.

For additional information regarding LACRIFILL Canalicular Gel and to place orders, interested parties can visit lacrifill.com.

About Nordic Group B.V.

Nordic Group B.V. is an international pharmaceutical company focused on specialty product development and commercialization. With roots in Europe, it has expanded its reach through strategic acquisitions and targeted developments in sectors such as Eye Care, Rheumatology, and Women's Health. The establishment of the company's foundation has cemented its status as a key player in the global pharmaceutical market.

About Nordic Pharma, Inc.

Nordic Pharma, Inc. is adept in partnering with global biopharmaceutical companies, bringing cutting-edge biotechnology and sterile manufacturing solutions to the market.

Safe Harbor Statement

This press release contains forward-looking statements related to Nordic Group and Nordic Pharma's business strategies and initiatives. Actual results may vary due to various factors, including market conditions and regulatory changes. Nordic Group and Nordic Pharma are not obligated to update any forward-looking statements publicly.

For inquiries, contact:
Nordic Pharma, Inc.
Kate Popova, Project Contracts Manager
Phone: 610-285-1699
Email: [email protected]
Gail Feerrar, Director of Sales and Marketing
Phone: 610-285-7152
Email: [email protected]